Sort   by:  
 Page size 
ProteomicsComparative proteomic and transcriptomic analysis of the impact of androgen stimulation and darolutamide inhibition on prostate cancer cells
Androgen receptor (AR) signaling is a major driver and therapy target in prostate cancer. Several inhibitors of AR function are approved for different stages of the disease and their impact on downstream gene transcription has been described. However, the ensuing effects of androgen and anti-androge...
ORGANISM(S): Homo sapiens (Human) 
2023-02-17 | PXD036962 | Pride
Andrigen receptor signalling Vcap Darolutamide 
GenomicsDarolutamide antagonizes androgen signaling by blocking enhancer and super-enhancer activation [ChIP-seq]
Darolutamide antagonizes androgen signaling by blocking enhancer and super-enhancer activation [ChIP-seq]
PRJNA624051 | ENA
GenomicsDarolutamide antagonizes androgen signaling by blocking enhancer and super-enhancer activation [RNA-seq]
Darolutamide antagonizes androgen signaling by blocking enhancer and super-enhancer activation [RNA-seq]
PRJNA624138 | ENA
GenomicsGATA2 up-regulation restores androgen receptor chromatin association and advances darolutamide resistance in prostate cancer
GATA2 up-regulation restores androgen receptor chromatin association and advances darolutamide resistance in prostate cancer
PRJNA1049031 | ENA
TranscriptomicsGATA2 up-regulation restores androgen receptor chromatin association and advances darolutamide resistance in prostate cancer
Darolutamide is an anti-androgen drug clinically used for prostate cancer therapy. Despite its efficacy, potential drug resistance poses significant challenges in the clinical setting. To better understand the molecular changes resulting from prolonged exposure to darolutamide, we developed a darolu...
ORGANISM(S): Homo sapiens 
2024-12-31 | GSE249437 | GEO
GenomicsRNA-sequencing of LNCaP prostate cancer cells with and without treatment of darolutamide
RNA-sequencing of LNCaP prostate cancer cells with and without treatment of darolutamide
PRJNA1176846 | ENA
GenomicsDarolutamide antagonizes androgen signaling by blocking enhancer and super-enhancer activation [ChIP-seq]
The androgen receptor (AR) antagonist darolutamide has very recently been approved for the treatment of non-metastatic castration resistant prostate cancer (PCa). Here we determined the genome-wide effects of darolutamide on cis-acting regulatory elements involved in androgen signaling with a focus ...
ORGANISM(S): Homo sapiens 
2020-04-10 | GSE148358 | GEO
TranscriptomicsDarolutamide antagonizes androgen signaling by blocking enhancer and super-enhancer activation [RNA-seq]
The androgen receptor (AR) antagonist darolutamide has very recently been approved for the treatment of non-metastatic castration resistant prostate cancer (PCa). Here we determined the genome-wide effects of darolutamide on cis-acting regulatory elements involved in androgen signaling with a focus ...
ORGANISM(S): Homo sapiens 
2020-04-10 | GSE148397 | GEO
UnknownDarolutamide For Castration-Resistant Prostate Cancer.
Not available
S-EPMC6816030 | biostudies-literature
GenomicsGATA2 upregulation restores androgen receptor chromatin association and advances darolutamide resistance in prostate cancer (RNA-Seq)
GATA2 upregulation restores androgen receptor chromatin association and advances darolutamide resistance in prostate cancer (RNA-Seq)
PRJNA1049034 | ENA
Sort   by:  
 Page size